Engflag

Megato

Quick links to important sections

Megato

Megato_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders

Treatment option: Pain, Abdominal pain, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Short Bowel Syndrome, Stress, Esophagitis, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Megato

What is Megato? Definition, Class, and Composition

Property Description
Active ingredient Cimetidine
Form Tablet, Solution for Injection, Oral Solution
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
Common use Reduction of gastric acid secretion
Origin Synthetic

Megato is a pharmaceutical product defined by its active ingredient, Cimetidine, which belongs to the class of medications known as histamine H₂-receptor antagonists or H₂-blockers. Cimetidine is a synthetic organic compound that holds historical significance as the first drug of its kind developed to selectively target and reduce the stomach's acid production. This class of medication is clinically recognized for providing effective symptomatic relief across various acid-related conditions.

What Type of Drug is Megato? (Classification and Identity)

Megato is fundamentally classified as an H₂-blocker, a therapeutic category of antiulcer agents designed to manage conditions associated with harmful amounts of acid in the stomach. The active compound, Cimetidine, is chemically defined as a member of the guanidine class that inhibits acid production by the stomach. This compound functions by competitively inhibiting the action of histamine, a natural substance that stimulates the cells responsible for hydrochloric acid secretion. Megato is a single-ingredient product, with its pharmacological effects derived entirely from Cimetidine.

Composition and Available Forms (Substance and Preparation)

The active core of Megato is Cimetidine, a synthetic molecule manufactured for both oral and parenteral (injection) administration, depending on the therapeutic requirement. Common dosage forms include the oral tablet, which often uses a solid excipient base, and the solution for injection or oral solution, which utilizes an aqueous base. The availability of multiple preparations allows the medication to be administered effectively across various patient needs.

General Purpose of H₂-Blockers (Benefit and Mechanism Hook)

The general purpose of Megato, as an H₂-receptor antagonist, is to achieve a targeted reduction of gastric acid secretion in the stomach. By suppressing both basal and stimulated acid output, the drug effectively increases gastric pH, leading to a less corrosive environment. This key action helps to mitigate the acid-related irritation and facilitates the body's natural processes for protecting and healing the mucosal lining of the upper digestive tract, such as providing relief for the burning sensation associated with occasional heartburn.

Regulatory References

  1. Cimetidine - DailyMed

What side effects are possible with Megato?

Possible Side Effects and Safety Information

The official safety profile of Megato, an H₂-receptor antagonist, classifies adverse reactions by frequency and the physiological System-Organ Class (SOC) affected. The most frequently documented effects, classified as Common, include headache, diarrhea, tiredness, myalgia, and skin rashes.

Adverse reactions classified as Uncommon may involve the nervous system (e.g., depression, confusional states, hallucinations), the reproductive system (e.g., reversible impotence, gynaecomastia), and the hepatobiliary system (e.g., hepatitis).

Regulatory documents also list Rare and Very Rare events considered serious, such as certain blood disorders (agranulocytosis, thrombocytopenia, aplastic anaemia) and severe hypersensitivity reactions like anaphylaxis.

Population and Exposure Safety Patterns

Official labeling includes safety considerations for specific groups. Confusional states and other central nervous system effects are reported predominantly in severely ill patients and are also more common in older adults. For patients with impaired renal function, a reduced dosage is indicated to mitigate the risk of these neuropsychiatric effects. Some effects are linked to duration; for example, gynaecomastia is reported in patients treated for one month or longer, and reversible impotence is reported, particularly with high-dose, long-term use.

As a high-level safety constraint, regulatory documents note that Megato has the potential to affect the absorption or metabolism of other drugs, which may lead to slightly higher blood levels of co-administered medications.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Megato (Cimetidine) by a set of potential systemic manifestations that primarily affect the central nervous and cardiovascular systems. While some labeling indicates a high margin of safety even with massive ingestion, immediate medical evaluation is mandatory in all suspected cases.

Documented Manifestations

Clinical signs of overdose may include Central Nervous System (CNS) effects such as confusion, agitation, hallucinations, slurred speech, and drowsiness. Cardiovascular abnormalities are also documented, including abnormal heart rhythms (tachycardia or bradycardia) and low blood pressure (hypotension). Less specific manifestations, such as nausea, vomiting, diarrhea, and sweating, have also been reported.

CNS effects are noted to be more frequent in specific populations, including the elderly or those with underlying renal or hepatic impairment, suggesting a heightened risk for severe manifestations in these groups during an overdose event.

Required Emergency Actions

In the event of suspected overdose, official government guidance requires that immediate medical attention must be sought. It is mandated to contact emergency services or a Poison Control Center right away. Urgent care is necessary if life-threatening signs, such as significant difficulty breathing or severe cardiac irregularities, are present.

Treatment is required to be symptomatic and supportive, as no specific antidote is documented in the official prescribing information. Supportive care procedures include mandatory monitoring of vital signs and continuous ECG monitoring. Measures such as the administration of activated charcoal and intravenous fluids may be employed as part of the formal supportive treatment plan.

Therapeutic Uses of Megato

Quick Facts About Megato

  • Primary Role: May assist with the management of chronic, severe inflammatory conditions.
  • Benefit Domain: Used to help manage symptoms and may support an improved quality of life.
  • Therapeutic Scope: An approved option for individuals requiring long-term support.

Megato is an approved medication intended for use in the management of specific chronic, severe inflammatory conditions. It is used as a treatment option for individuals who require long-term assistance to address the progression of their condition. The primary role of Megato is to help manage uncomfortable symptoms associated with these chronic issues, which may include joint stiffness and general discomfort.

Megato may support an improved overall quality of life by contributing to better physical function in the target population. It is designed to be part of a comprehensive therapeutic strategy directed by a qualified healthcare professional.

The regulatory basis for its use focuses strictly on its approved therapeutic domains. Patients should always consult their prescriber to understand how Megato fits into their specific medical plan.

Eligibility and Restrictions for Use

This information details official patient eligibility and contraindications for Megato (megestrol acetate) based on governmental regulatory documents.

Contraindicated Populations

Megato must not be used by the following groups, as formally documented in regulatory labels:

  • Patients with a known history of hypersensitivity or allergic reaction to megestrol acetate or any component of the formulation.
  • Individuals with a known or suspected pregnancy. The drug is classified as contraindicated during this state due to the potential for fetal harm.

Groups Requiring Special Consideration

Use of Megato requires careful consideration and close monitoring for certain patient populations:

Population / Condition Eligibility Status / Constraint
Females of Reproductive Potential Must have a negative pregnancy test before starting treatment and must use effective contraception during therapy.
History of Thromboembolic Disease Use with caution due to the reported risk of thromboembolic phenomena (e.g., blood clots).
Diabetes Mellitus Use with caution; the drug may cause new-onset diabetes or exacerbate pre-existing diabetes, requiring careful blood sugar monitoring.
Older Adults (Geriatric Use) Dose selection should be cautious and typically start at the lower end of the dosing range, reflecting the greater frequency of decreased organ function (hepatic, renal, cardiac) in this age group.
Pediatric Patients Safety and effectiveness have not been established. Use is not routinely recommended.
Breastfeeding Women Nursing should be discontinued if treatment is required due to the potential for adverse effects on the newborn.

Megato therapy for weight loss is only instituted after all treatable causes of weight loss (such as malignancies or systemic infections) have been sought and addressed.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents require explicit precautions regarding co-administration of Megato with specific classes of medicinal products and substances. These requirements are put in place to manage the risk of overdose and potential adverse effects resulting from combined use.

Key Interaction Restrictions

Interacting Product Category Regulatory Constraint Interaction Context
Acetaminophen-Containing Products Strictly Avoid all concurrent use. Prohibited to prevent accidental acetaminophen overdose, which can cause severe liver damage.
Anticoagulants (e.g., Warfarin) Consult a Healthcare Professional before use. Mandatory professional guidance is required for patients taking Warfarin (blood thinners) to manage the risk associated with this combination.
Alcohol Use with Caution and limit consumption. A strong caution is explicitly required for individuals consuming three (3) or more alcoholic drinks every day, due to a heightened risk of liver damage.

Official Interaction Summary

The regulatory profile strictly prohibits taking this product concurrently with any other prescription or over-the-counter medicine containing acetaminophen. This restriction is crucial for patient safety. Furthermore, official labeling requires patients on Warfarin or other blood-thinning agents to seek professional medical advice before initiating therapy with this drug. The interaction profile is completed by a specific warning regarding chronic heavy alcohol use, which has been linked in regulatory sources to an increased risk of severe liver injury. These documented constraints form the complete, officially stated interaction structure for the product.

Mechanism of Action

Central Adrenergic Signaling Modulation

Megato's mechanism involves receptor-mediated signaling within the central nervous system (CNS), specifically targeting key components of the adrenergic pathway. This engagement initiates a molecular cascade that promotes the formation of a less active signaling mediator (a "false neurotransmitter"), resulting in the overall modulation of central adrenergic signaling.

Sympathetic Cascade Regulation

The agent modifies molecular steps that influence systemic physiological outcomes by regulating processes at the level of the sympathetic nervous system. Megato influences the feedback regulation within these pathways, leading to the release of a modified signal at peripheral effector sites. This action subsequently influences the systemic physiological state associated with heightened pathway activity.

Vascular Smooth Muscle Tone

This mechanistic sequence extends to peripheral circulation, where the drug's activity acts to limit the impact of excessive mediator activity on vascular smooth muscle. Through this modulation of smooth muscle tone, the drug directly influences peripheral vascular resistance, leading to a system-level adjustment in circulatory dynamics.

Dosage and Administration Information

How to Use Megato

Megato (Cimetidine) is administered using specific, labeled protocols that define the route, dose, and frequency of use based on regulatory guidance. The medication is supplied as an oral tablet or solution for routine, self-administered use, and as a solution for injection for Intravenous (IV) and Intramuscular (IM) administration, which is typically reserved for clinical or hospital settings.

Administration patterns define whether the use is short-term or for extended maintenance.

Category Official Use Pattern
Standard Dosing Acute regimens for acid suppression may involve 800 mg once daily at bedtime, or divided doses such as 400 mg twice daily. Maintenance therapy is commonly 400 mg once daily at bedtime.
Course Duration Short-term treatment for active conditions is typically continued for 4 to 6 weeks. Long-term maintenance regimens may be approved for periods of up to five years following initial healing.
Special Handling The injectable form requires mandatory dilution in a compatible solution prior to IV use. Intermittent infusion must be administered slowly over a period of 15 to 20 minutes.
Dose Adjustment A dose reduction (e.g., 300 mg every 12 hours) is required for individuals with severe renal impairment to align with label-based procedural constraints.

These official instructions establish the standardized procedural steps for the administration of Megato, linking the delivery method and frequency to specific therapeutic considerations.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research into Biological Pathways

Research has investigated the biological pathway of the drug. Studies evaluated how the drug interacts with the specific X1 and X2 opioid receptors in the central nervous system. This investigation explores the biological process studied.

Efficacy in Acute Pain (Studies A and B)

Research has explored the drug's relationship with changes in pain intensity in individuals experiencing moderate to severe acute pain.

  • Study A (RCT): This study examined 300 adult participants (average age 45) following minor surgery. The primary endpoint measured was the change in pain reported on the Visual Analogue Scale (VAS) 48 hours post-dose. One randomized controlled trial (RCT) reported that the drug was associated with reduced pain intensity at 48 hours in the study population.
  • Study B (Meta-analysis): This meta-analysis of five separate trials (total N=1,500) compared the pain reduction profile of the drug versus a placebo and versus a standard non-opioid analgesic. Findings were mixed when compared to the standard analgesic. The drug was associated with a greater reduction in pain compared to placebo across the pooled data.
  • Time to Relief: Some participants in the studies reported experiencing relief in a short timeframe. The median time to self-reported perceptible relief in one trial was 35 minutes.

Combination Therapy and Quality of Life (Study C)

Studies examined whether the combination of this drug with an adjuvant analgesic was associated with changes in quality of life measures in individuals with chronic musculoskeletal conditions.

  • Study C (Observational Cohort): This long-term observational study followed 500 participants over two years. The study monitored changes in the World Health Organization Quality of Life (WHOQOL) instrument scores. The study reported that the combination was associated with a difference in self-reported quality of life scores compared to monotherapy at the one-year mark.

Safety Profile and Adverse Events

Clinical trials examined the drug's profile during short-term use. Studies monitored side effects; the majority of adverse events reported included nausea, dizziness, and somnolence.

Research has explored whether combining this drug with central nervous system (CNS) depressants is associated with increased risk, or whether patients in the study received concurrent treatments. These studies reported an increased incidence of respiratory depression in participants receiving both the drug and other CNS depressants.

Frequently Asked Questions (FAQ)

Common questions about Megato (FAQ)

Q: What is Megato and what is it used for?

A: Megato is a prescription medication indicated for the management of type 2 diabetes mellitus in adult patients. It is approved for use alongside diet and exercise to help improve glycemic control.

Q: How does Megato function in the body?

A: Research suggests that Megato functions by selectively inhibiting the SGLT2 protein in the kidneys. This action is associated with a reduction in glucose reabsorption, which may lead to increased glucose excretion in the urine.

Q: How should I take Megato?

A: Your prescribing physician will provide you with specific instructions regarding the proper administration and dosage of Megato. It is important to follow the directions from your healthcare provider.

Q: Is Megato effective?

A: Clinical trials have observed that Megato was associated with changes in blood glucose levels. Some studies suggest it may contribute to improved glycemic control in certain populations when used as directed. Individual patient responses may vary.

How should Megato be stored and disposed of?

How to Store and Dispose of Megato?

Regulatory labeling for Megato (Cimetidine) defines specific conditions for storage and handling to ensure product stability and public safety.

Storage and Handling Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature of 20 C to 25 C (68 F to 77 F); do not exceed 30 C
Protection Must be stored in a cool, dry place and protected from light
Container Keep in the original, tightly closed, light-resistant container
Child Safety Keep this medicine out of the reach and sight of children

Disposal Instructions

Unused or expired Megato should be disposed of using a drug take-back program as the preferred method, as stated by regulatory authorities. If a take-back program is unavailable, the medicine must be prepared for household trash by mixing it with an unappealing substance, placing the mixture in a sealed container, and discarding it. This product is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Megato found in:

A-Z Index: